총 157페이지
144페이지 본문시작
Ⅶ.부록
TableA.4. 가축 및 축·수산물 유래Campylobacter spp.의 MIC 검사에 사용한 항생제 종류 및 breakpoints
Breakpoints (㎍/㎖)
Antimicrobial
Antimicrobial agents
Range tested
Reference
C.jejuni
C.coli
subclass
(Abbreviation)
(㎍/㎖)
1)
Aminoglycosides
Gentamicin (GEN)
0.12-32
≥4
NARMS
1)
Fluoroquinolone
Ciprofloxacin (CIP)
0.015-64
≥1
NARMS
1)
Ketolide
Telithromycin (TEL)
0.015-8
≥8
NARMS
1)
1)
Azithromycin (AZM)
0.015-64
≥0.5
≥1
NARMS
Macrolides
1)
1)
Erythromycin (ERY)
0.03-64
≥8
≥16
NARMS
1)
Quinolone
Nalidixic acid (NAL)
4-64
≥32
NARMS
1)
1)
Lincosamides
Clindamycin (CLI)
0.03-16
≥1
≥2
NARMS
1)
Phenicols
Florfenicol (FFC)
0.06-64
≥8
NARMS
1)
1)
Tetracyclines
Tetracycline (TET)
0.06-64
≥2
≥4
NARMS
1) National Antimicrobial Resistance Monitoring System, 2013
Table A.5. 가축 및 축·수산물 유래Staphylococcusaureus의 MIC 검사에 사용한 항생제 종류 및 breakpoints
Antimicrobial
Antimicrobial Agents
Range tested
Breakpoints
Reference
subclass
(Abbreviation)
(㎍/㎖)
(㎍/㎖)
1)
Gentamicin (GEN)
1-32
≥16
CLSI
1)
Aminoglycosides
Kanamycin (KAN)
4-64
≥64
CLSI
3)
Streptomycin (STR)
1-16
ND
-
1)
Ansamycins
Rifampin (RIF)
0.016-0.5
≥4
CLSI
1)
Penicillin
Penicillin (PEN)
0.12-2
≥0.25
CLSI
1)
Cephamycin
Cefoxitin (FOX)
0.5-16
≥8
CLSI
1)
Fluoroquinolone
Ciprofloxacin (CIP)
0.25-8
≥4
CLSI
1)
Glycopeptide
Vancomycin (VAN)
1-16
≥16
CLSI
1)
Macrolides
Erythromycin (ERY)
0.25-8
≥8
CLSI
1)
Oxazolidinones
Linezolid (LNZ)
1-8
≥8
CLSI
1)
Sulfamethoxazole (SMX)
64-512
≥512
CLSI
Folate pathway
inhibitors
1)
Trimethoprim (TMP)
2-32
≥16
CLSI
1)
Lincosamides
Clindamycin (CLI)
0.12-4
≥4
CLSI
1)
Phenicols
Chloramphenicol (CHL)
4-64
≥32
CLSI
2)
Pseudomonic acid
Mupirocin (MUP)
0.5-256
>256
EUCAST
Quinupristin/
1)
Streptogramins
0.5-4
≥4
CLSI
Dalfopristin (SYN)
1)
Tetracyclines
Tetracycline (TET)
0.5-16
≥16
CLSI
2)
Others
Fusidate (FUS)
0.5-4
≥2
EUCAST
3)
Pleuromutilins
Tiamulin (TIA)
0.5-4
ND
-
1) Clinical Laboratory Standards Institute, M100, 2018
2) The European Committee on Antimicrobial Susceptibility Testing
3) ND, Not determined
140
TableA.4. 가축 및 축·수산물 유래Campylobacter spp.의 MIC 검사에 사용한 항생제 종류 및 breakpoints
Breakpoints (㎍/㎖)
Antimicrobial
Antimicrobial agents
Range tested
Reference
C.jejuni
C.coli
subclass
(Abbreviation)
(㎍/㎖)
1)
Aminoglycosides
Gentamicin (GEN)
0.12-32
≥4
NARMS
1)
Fluoroquinolone
Ciprofloxacin (CIP)
0.015-64
≥1
NARMS
1)
Ketolide
Telithromycin (TEL)
0.015-8
≥8
NARMS
1)
1)
Azithromycin (AZM)
0.015-64
≥0.5
≥1
NARMS
Macrolides
1)
1)
Erythromycin (ERY)
0.03-64
≥8
≥16
NARMS
1)
Quinolone
Nalidixic acid (NAL)
4-64
≥32
NARMS
1)
1)
Lincosamides
Clindamycin (CLI)
0.03-16
≥1
≥2
NARMS
1)
Phenicols
Florfenicol (FFC)
0.06-64
≥8
NARMS
1)
1)
Tetracyclines
Tetracycline (TET)
0.06-64
≥2
≥4
NARMS
1) National Antimicrobial Resistance Monitoring System, 2013
Table A.5. 가축 및 축·수산물 유래Staphylococcusaureus의 MIC 검사에 사용한 항생제 종류 및 breakpoints
Antimicrobial
Antimicrobial Agents
Range tested
Breakpoints
Reference
subclass
(Abbreviation)
(㎍/㎖)
(㎍/㎖)
1)
Gentamicin (GEN)
1-32
≥16
CLSI
1)
Aminoglycosides
Kanamycin (KAN)
4-64
≥64
CLSI
3)
Streptomycin (STR)
1-16
ND
-
1)
Ansamycins
Rifampin (RIF)
0.016-0.5
≥4
CLSI
1)
Penicillin
Penicillin (PEN)
0.12-2
≥0.25
CLSI
1)
Cephamycin
Cefoxitin (FOX)
0.5-16
≥8
CLSI
1)
Fluoroquinolone
Ciprofloxacin (CIP)
0.25-8
≥4
CLSI
1)
Glycopeptide
Vancomycin (VAN)
1-16
≥16
CLSI
1)
Macrolides
Erythromycin (ERY)
0.25-8
≥8
CLSI
1)
Oxazolidinones
Linezolid (LNZ)
1-8
≥8
CLSI
1)
Sulfamethoxazole (SMX)
64-512
≥512
CLSI
Folate pathway
inhibitors
1)
Trimethoprim (TMP)
2-32
≥16
CLSI
1)
Lincosamides
Clindamycin (CLI)
0.12-4
≥4
CLSI
1)
Phenicols
Chloramphenicol (CHL)
4-64
≥32
CLSI
2)
Pseudomonic acid
Mupirocin (MUP)
0.5-256
>256
EUCAST
Quinupristin/
1)
Streptogramins
0.5-4
≥4
CLSI
Dalfopristin (SYN)
1)
Tetracyclines
Tetracycline (TET)
0.5-16
≥16
CLSI
2)
Others
Fusidate (FUS)
0.5-4
≥2
EUCAST
3)
Pleuromutilins
Tiamulin (TIA)
0.5-4
ND
-
1) Clinical Laboratory Standards Institute, M100, 2018
2) The European Committee on Antimicrobial Susceptibility Testing
3) ND, Not determined
140
144페이지 본문끝
메뉴
현재 포커스의 아래내용들은 동일한 컨텐츠를 가지고 페이지넘김 효과및 시각적 효과를 제공하는 페이지이므로 스크린리더 사용자는 여기까지만 낭독하시고 위의 페이지이동 링크를 사용하여 다음페이지로 이동하시기 바랍니다.